23andMe Holding Co. (NASDAQ:ME) Q4 2022 Earnings Conference Call May 26, 2022 4:30 PM ET
Company Participants
Wade Walke - Vice President of Investor Relations
Anne Wojcicki - Co-Founder and Chief Executive Officer
Kenneth Hillan - Chief Therapeutics Officer
Steve Schoch - Chief Financial Officer
Conference Call Participants
Tiago Fauth - Credit Suisse AG
Daniel Grosslight - Citigroup Inc.
Operator
Good morning, and welcome to the 23andMe's Fiscal Year 2022 Fourth Quarter and Year-End Financial Results Conference Call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session.
I would now like to turn the call over to Wade Walke, Vice President of Investor Relations to lead off the call. Thank you. Please go ahead.
Wade Walke
Thank you. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the quarter and fiscal year. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event.
Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to, management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled forward-looking statements in our press release which applies to this call. Also, please refer to our SEC filings which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures, important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release.
Joining us on today's call are Anne Wojcicki, our Chief Executive Officer and Co-Founder; Kenneth Hillan, our Chief Therapeutics Officer; and Steve Schoch, our Chief Financial Officer
And now, I'd like to turn the call over to Anne.
Anne Wojcicki
Thank you, Wade. We are excited about the steps we have taken over the last year and specifically over the last several months to begin to integrate genetics into everyday care with the ultimate goal of making personalized healthcare a reality. One of the unique aspects of our approach is that we will be able to offer people the ability to access and learn about their DNA and then take proactive preventative steps to manage their health and wellbeing through guidance from our genetically trained Lemonaid clinicians.